Literature DB >> 1827591

Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.

D Rouy1, P Grailhe, F Nigon, J Chapman, E Anglés-Cano.   

Abstract

Apoprotein(a), (apo[a]), the specific antigen of lipoprotein(a) (Lp[a]), consists of structural domains (a serine protease unit, kringles 4 and 5) with marked homology to those of the corresponding domains in plasminogen. In this study, we have investigated the impact of this unique structural mimicry on the binding and activation of plasminogen by fibrin-bound tissue-type plasminogen activator at the plasma-fibrin interface. We found that the total amount of plasmin generated on the surface of fibrin was decreased in the presence of high concentrations of Lp(a): 197 +/- 65 fmol in plasmas with greater than 60 mg/dl Lp(a) versus 287 +/- 112 fmol in control plasmas. A similar effect was also apparent in the corresponding euglobulin fractions (554 +/- 169 fmol versus 754 +/- 310 fmol), the latter lacking the plasminogen-binding proteins alpha 2-antiplasmin and histidine-rich glycoprotein, but containing Lp(a). The difference between plasma samples was significant (p less than 0.05) as calculated from the percent decrease in plasmin generated from plasmas with high levels of Lp(a) relative to that generated in the paired controls with low Lp(a) levels. The involvement of Lp(a) was verified in a reconstituted system consisting of normal human plasma supplemented with 100 mg/dl of either purified Lp(a) or low density lipoprotein. Lp(a) produced a decrease of 30% in the generation of plasmin (180 fmol versus 255 fmol in plasma, and 485 fmol versus 705 fmol in the euglobulin fraction). Moreover, using a radiolabeled sheep antibody against human apo(a), we were able to demonstrate the binding of 40 fmol Lp(a) to fibrin during ongoing plasminogen activation. These results indicate that Lp(a) impairs the binding of plasminogen to fibrin and thereby decreases the generation of plasmin by occupying C-terminal lysine residues unveiled on the fibrin surface by plasmin degradation as recently reported (Circulation 1990;82[suppl III]:III-92). In consequence, impairment of fibrinolysis and accumulation of Lp(a) at sites of vascular injury may occur, factors that may be important in the development of atherosclerosis and associated thrombosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827591     DOI: 10.1161/01.atv.11.3.629

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  26 in total

Review 1.  Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role.

Authors:  A M Scanu
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

2.  Lipoprotein(a)

Authors:  J Scott
Journal:  BMJ       Date:  1991-09-21

3.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

Review 4.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

Review 5.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

6.  Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.

Authors:  Q Xiao; M J Danton; D P Witte; M C Kowala; M T Valentine; J L Degen
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

7.  Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.

Authors:  N W Boonmark; X J Lou; Z J Yang; K Schwartz; J L Zhang; E M Rubin; R M Lawn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

8.  Farnesoid X receptor represses hepatic human APOA gene expression.

Authors:  Indumathi Chennamsetty; Thierry Claudel; Karam M Kostner; Anna Baghdasaryan; Dagmar Kratky; Sanja Levak-Frank; Sasa Frank; Frank J Gonzalez; Michael Trauner; Gert M Kostner
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

Review 9.  Dyslipidemias in the prevention of cardiovascular disease: risks and causality.

Authors:  Ian Graham; Marie-Therese Cooney; David Bradley; Alexandra Dudina; Zeljko Reiner
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

10.  Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism.

Authors:  P C Harpel; V T Chang; W Borth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.